Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib plus nivolumab and ipilimumab versus nivolumab and ipilimumab in previously untreated advanced or metastatic intermediate- or poor-risk renal cell carcinoma
2024-515616-47-00Phase 3Authorised
- Sponsor
- Exelixis, Inc.
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Cabozantinib + nivolumab + ipilimumab with Placebo + nivolumab + ipilimumab (2 arms). Primary endpoint: Progression-free survival. Planned start Oct 2019; status: authorised.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2024-515616-47-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515616-47-00.